Member Article

Post-pandemic liquidity is supercharging M&A deals in MedTech, says ICON Corporate Finance.

The tectonic shift in the way that medical services have needed to be delivered following Covid-19 - moving online, delivering remote monitoring of patients - has created a huge opportunity for MedTech companies to capitalise on an upsurge in sector demand and a desire to boost investors’ robust balance sheets, says ICON Corporate Finance, the tech-focussed investment bank. The pandemic, in its view, has accelerated the shift to digital and smart technological solutions driving the future of patient care.

Having recently advised Quantex, a leader in single-use, recyclable pump technology, on its sale to global pump solution experts PSG, ICON predicts that the market for smaller, lighter medical monitoring devices will see the sector continue to thrive.

London-based Quantex’s revolutionary single-use positive displacement pump technology helps medical professionals deliver precision and micro-dosing across a wide range of pressures, temperatures, viscosities, and flow rates. Its disposable pumps offer patients hygienic and sterile applications, maximising flexibility and delivering the highest quality patient care.

The deal expands PSG’s reach into biopharma and hygienic applications and sees Quantex become part of Dover Corporation, a diversified global manufacturer delivering innovative equipment and components, consumable supplies, aftermarket parts, software and digital solutions and support services.

Commenting on the deal, Karl Buscher PSG’s President said: “The addition of Quantex expands Dover’s reach into medical and biopharma applications. We are excited to add Quantex’s game-changing technology to our portfolio. The Quantex recyclable portfolio of products will enable us to expand our single-use application reach across the biopharma, hygienic, food and beverage and industrial markets.”

James Kenward and Simon Moynagh, ICON’s M&A advisers to Quantex, added: “We are delighted to work with founder, Dr Paul Pankhurst, and his team on the sale of Quantex to the global experts in the field, Dover’s subsidiary PSG. This is a fantastic outcome for shareholders, employees and the game-changing technology of Quantex. Dover’s PSG provides the global scale required to fully realise the power of Quantex’s technology across multiple industries.”

Dr Paul Pankhurst, Founder and CEO of Quantex, commented on ICON Corporate Finance, “I have been very impressed by the dedication and advice of ICON, who have been critical to a successful outcome.”

This was posted in Bdaily's Members' News section by Charley .